Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NYSE:PRME NASDAQ:ZNTL NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$7.07+0.7%$7.63$6.10▼$28.67$486.16M1.41209,017 shs370,904 shsPRMEPrime Medicine$4.07-0.2%$3.88$1.11▼$5.17$547.72M2.382.55 million shs2.70 million shsZNTLZentalis Pharmaceuticals$1.49-4.5%$1.52$1.01▼$5.44$107.48M1.76805,086 shs505,455 shsZVRAZevra Therapeutics$7.75-2.5%$10.44$6.19▼$13.16$435.05M1.561.27 million shs1.81 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics0.00%-1.26%-4.20%-15.53%-73.78%PRMEPrime Medicine0.00%+9.41%+11.81%+178.77%-0.49%ZNTLZentalis Pharmaceuticals0.00%-14.86%+0.68%+11.19%-54.15%ZVRAZevra Therapeutics0.00%-13.41%-12.92%-15.12%+4.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$7.07+0.7%$7.63$6.10▼$28.67$486.16M1.41209,017 shs370,904 shsPRMEPrime Medicine$4.07-0.2%$3.88$1.11▼$5.17$547.72M2.382.55 million shs2.70 million shsZNTLZentalis Pharmaceuticals$1.49-4.5%$1.52$1.01▼$5.44$107.48M1.76805,086 shs505,455 shsZVRAZevra Therapeutics$7.75-2.5%$10.44$6.19▼$13.16$435.05M1.561.27 million shs1.81 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics0.00%-1.26%-4.20%-15.53%-73.78%PRMEPrime Medicine0.00%+9.41%+11.81%+178.77%-0.49%ZNTLZentalis Pharmaceuticals0.00%-14.86%+0.68%+11.19%-54.15%ZVRAZevra Therapeutics0.00%-13.41%-12.92%-15.12%+4.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.67Moderate Buy$22.22214.32% UpsidePRMEPrime Medicine 2.75Moderate Buy$8.92119.08% UpsideZNTLZentalis Pharmaceuticals 2.67Moderate Buy$8.20450.34% UpsideZVRAZevra Therapeutics 2.89Moderate Buy$23.71205.99% UpsideCurrent Analyst Ratings BreakdownLatest ZNTL, ZVRA, PRME, and BCYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025ZVRAZevra TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/13/2025ZVRAZevra TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$19.00 ➝ $18.008/12/2025BCYCBicycle TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$22.00 ➝ $10.008/12/2025BCYCBicycle TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$17.00 ➝ $13.008/11/2025BCYCBicycle TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$27.008/11/2025BCYCBicycle TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$48.00 ➝ $44.008/8/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.008/7/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/7/2025ZNTLZentalis PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$6.00 ➝ $5.007/17/2025BCYCBicycle TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$32.00 ➝ $25.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$19.28M25.39N/AN/A$11.48 per share0.62PRMEPrime Medicine$4.96M110.40N/AN/A$1.37 per share2.97ZNTLZentalis Pharmaceuticals$26.87M4.00N/AN/A$4.73 per share0.32ZVRAZevra Therapeutics$62.02M7.01N/AN/A$0.74 per share10.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$169.03M-$3.51N/AN/AN/A-1,257.00%-32.43%-26.80%10/30/2025 (Estimated)PRMEPrime Medicine-$198.13M-$1.56N/AN/AN/AN/A-107.87%-74.97%N/AZNTLZentalis Pharmaceuticals-$165.84M-$2.26N/AN/AN/AN/A-51.62%-40.28%11/11/2025 (Estimated)ZVRAZevra Therapeutics-$105.51M-$0.21N/A38.75N/A4.33%-112.40%-37.67%11/11/2025 (Estimated)Latest ZNTL, ZVRA, PRME, and BCYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025BCYCBicycle Therapeutics-$0.95-$1.14-$0.19-$1.14$9.43 million$2.90 million8/6/2025Q2 2025ZNTLZentalis Pharmaceuticals-$0.56-$0.37+$0.19-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4535.53%N/AN/A N/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A10.3910.39PRMEPrime MedicineN/A6.506.50ZNTLZentalis PharmaceuticalsN/A7.997.99ZVRAZevra Therapeutics0.527.857.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%PRMEPrime Medicine70.37%ZNTLZentalis PharmaceuticalsN/AZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics22.90%PRMEPrime Medicine22.74%ZNTLZentalis Pharmaceuticals1.90%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.25 million53.40 millionOptionablePRMEPrime Medicine234134.57 million100.38 millionOptionableZNTLZentalis Pharmaceuticals16072.14 million70.76 millionOptionableZVRAZevra Therapeutics2056.14 million54.79 millionOptionableZNTL, ZVRA, PRME, and BCYC HeadlinesRecent News About These CompaniesDo Zevra Therapeutics' (ZVRA) New MIPLYFFA Data Reshape the Rare Disease Innovation Narrative?September 13 at 2:28 PM | finance.yahoo.comWoodline Partners LP Acquires 476,032 Shares of Zevra Therapeutics, Inc. $ZVRASeptember 12 at 6:40 AM | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Large Increase in Short InterestSeptember 9, 2025 | marketbeat.comZevra Therapeutics, Inc. $ZVRA Stock Holdings Trimmed by Adage Capital Partners GP L.L.C.September 7, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $23.71 Consensus Target Price from AnalystsSeptember 6, 2025 | americanbankingnews.comZevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)September 4, 2025 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 4, 2025 | marketbeat.comZevra Therapeutics, Inc. $ZVRA Shares Sold by Nantahala Capital Management LLCSeptember 3, 2025 | marketbeat.comRetirement Planning Co of New England Inc. Has $4.12 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRASeptember 2, 2025 | marketbeat.comWellington Management Group LLP Purchases New Shares in Zevra Therapeutics, Inc. $ZVRASeptember 2, 2025 | marketbeat.comVelan Capital Investment Management LP Increases Stake in Zevra Therapeutics, Inc. $ZVRAAugust 31, 2025 | marketbeat.comZevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)August 28, 2025 | globenewswire.comZevra Therapeutics, Inc. $ZVRA Holdings Boosted by Stonepine Capital Management LLCAugust 26, 2025 | marketbeat.comZevra Therapeutics to Participate at Upcoming Investor Conferences in SeptemberAugust 26, 2025 | globenewswire.comZacks Research Downgrades Zevra Therapeutics (NASDAQ:ZVRA) to HoldAugust 22, 2025 | marketbeat.comZevra Therapeutics rumor highlighted in Betaville blogAugust 21, 2025 | msn.comZevra Therapeutics gains amid takeover speculationAugust 21, 2025 | msn.comZevra Therapeutics (NASDAQ:ZVRA) Director John Bode Buys 5,000 SharesAugust 21, 2025 | insidertrades.comZevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 4.4% - Should You Buy?August 17, 2025 | marketbeat.comCantor Fitzgerald Brokers Lower Earnings Estimates for ZVRAAugust 17, 2025 | marketbeat.comEquities Analysts Offer Predictions for ZVRA Q3 EarningsAugust 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZNTL, ZVRA, PRME, and BCYC Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$7.07 +0.05 (+0.71%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.98 -0.09 (-1.27%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Prime Medicine NYSE:PRME$4.07 -0.01 (-0.25%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.06 -0.02 (-0.37%) As of 09/12/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Zentalis Pharmaceuticals NASDAQ:ZNTL$1.49 -0.07 (-4.49%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.50 +0.01 (+0.34%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.Zevra Therapeutics NASDAQ:ZVRA$7.75 -0.20 (-2.52%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.99 +0.24 (+3.10%) As of 09/12/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
